You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.
The study, led by researchers from precision health firm Human Longevity, also uncovered phenotypic evidence supporting some pathogenic genetic findings.
The oncology division of Human Longevity performs next-generation sequencing services for pharmaceutical customers and generated $10 million in revenue in 2019.
The San Diego-based company plans to use the proceeds from the financing to enhance its Health Nucleus intelligence platform.
A judge has dismissed a lawsuit brought by Human Longevity against the J. Craig Venter Institute.
Human Longevity had filed the suit in July, alleging the misappropriation of trade secrets by Craig Venter, who founded both the company and the institute.
The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.
The scientists developed a metabolomic panel capable of predicting BMI and identifying subsets of at-risk patients with apparently healthy BMIs.
A brief recap of Genetics/Genomics news the week of Aug 31, 2018: Perosnalize Medicine Coalition, Enzo Biochem, Hoosier Cancer Research Network, Scor Global Life, and ALCF
Retraction Watch writes that a cancer researcher has had an eighth paper retracted.
Computational biologist James Taylor has died, according to Johns Hopkins University.
The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.
In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.